Nantes

• A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma Ended recruitment
  2023-503440-14-00 3 2021-03-08 Relapsed/Refractory Multiple Myeloma
• A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat … Ended recruitment
  2023-507695-52-00 5 2021-03-05 Mantle cell lymphoma
• Iberdomide as maintenance therapy after autologous stem cell transplantation in newly diagnosed multiple myeloma patients Ended recruitment
  2024-512354-21-00 4 2021-02-22 Newly diagnosed multiple myeloma
• Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible … Ended recruitment
  2024-513659-34-00 9 2021-02-12 Relapsed/Refractory aggressive B-NHL
• FIBRAPLO - Haplo-identical transplantation in patients with myleofibrosis Ended recruitment
  2024-513325-23-00 4 2021-02-03 Myelofibrosis
• This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat … Ended recruitment
  2023-507338-26-00 5 2021-02-01 Histologically documented gastric or gastroesophageal junction adenoca
• KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA … Ended recruitment
  2024-513252-15-00 4 2021-01-28 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
• A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended recruitment
  2024-514502-31-00 5 2021-01-11 Prurigo Nodularis
• A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease. Ended recruitment
  2023-508290-81-00 5 2020-12-18 Immunoglobulin G4-related disease (IgG4-RD)
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended recruitment
  2022-501645-70-00 5 2020-11-25 Crohns Disease
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended recruitment
  2023-509358-72-00 5 2020-11-23 Diffuse large B-cell lymphoma
• Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk … Ended recruitment
  2023-507153-16-00 5 2020-11-18 Higher-Risk Myelodysplastic Syndrome
• The USTAP CD trial USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study Ended recruitment
  2023-503380-42-00 6 2020-11-16 patient with moderate to severe Crohn's disease with at least one acti
• A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced C … Ended recruitment
  2024-517536-22-00 7 2020-09-22 Unresectable or metastatic cutaneous squamous cell carcinoma
• Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients Ended recruitment
  2024-516102-36-00 4 2020-07-29 Minimal Change Nephrotic Syndrom
• A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha … Ended recruitment
  2023-506588-32-00 5 2020-06-12 Relapsed and Lenalidomide-Refractory Multiple Myeloma
• Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of age Ended recruitment
  2022-501974-21-00 5 2020-04-01 Prevention of oral persistent infection caused by any of the human pap
• First-in-human study of ICT01 in patients with advanced-stage, relapsed/refractory cancer Ended recruitment
  2024-515560-30-00 7 2020-03-05 Advanced-stage, relapsed/refractory cancer
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Ended recruitment
  2024-511653-22-00 5 2020-02-12 Cutaneous Squamous Cell Carcinoma (CSCC)
• An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma Ended recruitment
  2023-506587-13-00 4 2020-01-30 Multiple Myeloma
• MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial Ended recruitment
  2024-512269-14-00 5 2020-01-27 GIant cell Arteritis
• A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap … Ended recruitment
  2022-501531-16-00 5 2020-01-24 esophageal carcinoma
• Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. Ended recruitment
  2023-510248-19-00 5 2020-01-21 Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Showing 577–600 of 787 trials